Pro-Dex (PDEX) Projected to Post Quarterly Earnings on Wednesday

Pro-Dex (NASDAQ:PDEX) is anticipated to post its Q3 2026 results before the market opens on Wednesday, April 29th. Analysts expect Pro-Dex to post earnings of $0.62 per share and revenue of $17.90 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, May 1, 2026 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, January 29th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.07. Pro-Dex had a return on equity of 22.53% and a net margin of 15.73%.The firm had revenue of $18.66 million during the quarter, compared to analysts’ expectations of $17.30 million.

Pro-Dex Stock Performance

Shares of NASDAQ PDEX opened at $50.74 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.03 and a quick ratio of 2.25. Pro-Dex has a one year low of $23.47 and a one year high of $70.26. The business’s 50-day moving average price is $46.98 and its two-hundred day moving average price is $40.16. The company has a market capitalization of $162.88 million, a P/E ratio of 14.92 and a beta of -0.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC acquired a new stake in shares of Pro-Dex in the 4th quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Pro-Dex in the second quarter worth $50,000. Bank of America Corp DE increased its position in Pro-Dex by 173.3% during the second quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 1,073 shares during the last quarter. Wells Fargo & Company MN increased its position in Pro-Dex by 65.4% during the fourth quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock worth $89,000 after buying an additional 915 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new position in Pro-Dex during the second quarter valued at about $105,000. Institutional investors own 15.28% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Pro-Dex in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.00.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.